Breast Cancer Research and Treatment **26**: 299-300, 1993.
© 1993 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 26

Adkins D S-3
Allred DC 191, 225
Amadori D 7
Azavedo E 207

Ballerini P 1
Bélanger A 253
Bearman SI S-11, S-19
Benedix MG 191
Benraad ThJ 289
Benz CC 181
Berland E 283
Bezwoda WR 247
Bolla M 283
Brandt ME 15
Brufman G 101

Cappelletti V 7, 275
Chambaz EM 283
Chedin M 283
Chetty U 89
Ciocca DR 237
Clark GM 225, 237
Côté J 253
Colonna M 283
Coradini C 275
Correale M 7
Covey DF 15

Daidone MG 7
Dajee D 247
de Goeij CCJ 289
Delvincourt C 267
Depisch D 49
Di Fronzo G 7, 275
Dolci S 1
Dorembus D 101
Dotzlaw H 149
Duca P 1
Dufton C S-11
Dunphy F S-3

Eckhardt S 41
Elledge RM 191, 225
Elliott RL 77
Elton RA 89
Encarnación C 237

Ferrari L 1
Fioravanti L 275
Franco RS 217
Fuqua SAW 117, 191, 225, 237

Greene GL 191

Haider K 49
Hamerton J 149
Harada T 55
Head JF 77
Hennequin E 267
Hill BT 23
Holm L-E 207
Horwitz KB 119

Ichinose Y 55

Jack W 89
Jardillier J-C 267
Jiang S-Y 139
Jones RB S-11, S-19
Jones RJ S-31
Jordan VC 139

Kahán Z 41
Kan N 55
Kaufmann M 181
Kennedy MJ S-31
Kienhuis CBM 289
Kinami S 67
Kinishita K 67
Kitagawa H 67
Kodama H 55
Koenders PG 289
Kornek G 49
Krieg SL 191
Kwasny W 49

Labrie F 253
Lehrer SP 175
Lei Y 163
LeMaistre CF S-1
Lepage M 253
Lewin A 101
Li L 55
Li S 253
Lower EE 217
Luce MC 181

Marron-Charriere J 283
Martelo OJ 217
Martinetti A 1
Matthes S S-11
McCoy JL 77
McGuire WL 191, 225, 237
Mérand Y 253
Meyers S S-11, S-19
Miksicek RJ 163
Miller MA 217
Miller WR 89
Miodini P 275
Miyazaki I 67
Mizukami Y 67
Montgomery PA 181
Mor-Yosef S 101
Moriguchi Y 55
Murphy LC 149

Nawaz Z 191

Nilsson B 207
Noguchi M 67
Nordevang E 207

O'Malley BW 191
Ohgaki K 55
Oriana S 1
Osborne CK 237

Paradiso A 7
Parker CJ 139
Parker MG 131
Petruska P S-3
Pirker R 49
Pourny C 267
Puett D 15
Pujol P 225
Purdy M S-19

Rabin JM 175
Ravdin PM 110
Riccobon A 7
Rochefort H 107
Rostaing-Puissant B 283
Ruedl C 275

Satoh K 55
Schachter BS 175
Scheithauer W 49
Schenk T 49
Schmutzler RK 175
Schwarz J 149
Schweitzer M 95
Scott GK 181
Secreto G 1
Seymour L 247
Shpall EJ S-11, S-19
Shyamala G 95
Silvestrini R 7, 275
Sluyser M 289
Souvignet C 283
Spencer V S-3
Spitzer G S-3
Stemmer SM S-11, S-19
Sugie T 55
Svane G 207
Szücs M 41

Takamura H 67
Thomas M 67
Thorpe S 107

Ulrich SJ 95
Uziely B 101

Velasquez W S-3
Veneroni S 7
Venturelli E 1
Vescernyés M 41

Wang Y 163
Watson DMA 89
Whelan RDH 23
Williams SF S-25

Yamasaki S 55

Zimniski SJ 15

Breast Cancer Research and Treatment **26**: 301-305, 1993.
© 1993 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 26

4-hydroperoxycyclophosphamide
in marrow purging S-19–S-23

adoptive immunotherapy
for liver metastases 55-65
alternative splicing
and estrogen receptor exon-skipping variants 163-174
and estrogen receptor variants 149-161
amifostine
in marrow purging S-19–S-23
aneuploidy
see ploidy
antiestrogens
ER point mutation changes structure-function relationship 139-147
pure steroidal antiestrogens and ER dimerization and half-life 131-137
responses, and estrogen receptor variants 117-118
see also tamoxifen
aromatase inhibitors
10-propargylestr-4-ene-3,17-dione in rat DMBA tumors 15-21
autologous bone marrow support
see bone marrow transplantation
autologous tumor killing activity
in immuno-chemotherapy for liver metastases 55-65

B-lymphocyte responses
to pokeweed mitogen and tumor antigens in breast cancer patients 77-88
BCNU
toxicity increase by high-dose cisplatin S-11–S-17
bone marrow transplantation
accelerated engraftment with G-CSF, purging, and CD34+ selection S-19–S-23
induction of autologous GVHD and antitumor activity S-31–S-40
preparative drug regimens S-3–S-9

cathepsin D
as a prognostic factor (discussion) 107-111
immunohistochemical determination and other prognostic factors 7-13
CD34+ selection
accelerated marrow engraftment S-19–S-23
chemotherapy
dose-intensive (minisymposium) S-1–S-40
mdr1 gene expression in primary vs. metastatic tumors 267-274
navelbine and mitomycin C in second line treatment 49-53
pharmacokinetics at high doses S-11–S-17
pharmacokinetics in directing drug dosing S-11–S-17
tandem non-cross-resistant combinations S-3–S-9
cisplatin
BCNU toxicity increase at high doses S-11–S-17
in tandem non-cross resistant chemotherapy combinations S-3–S-9
cyclic AMP binding proteins
and prognosis 89-94
cyclophosphamide
in mobilizing peripheral blood progenitor cells S-25–S-29
in tandem non-cross resistant chemotherapy combinations S-3–S-9
pharmacokinetic interactions at high doses S-11–S-17
to augment immunotherapy response 55-65
cyclosporine A
induction of GVHD and antitumor activity S-31–S-40

cytoxan
see cyclophosphamide

Depo-Provera (medroxyprogesterone acetate, MPA)
controlled release MPA, inhibition of DMBA rat mammary tumors 253-265
diet
fat intake and mammographic parenchymal pattern 207-215
DMBA rat mammary tumors
regression by a new aromatase inhibitor 15-21
DNA ploidy
see ploidy
dose-intensive therapy
in breast cancer (minisymposium) S-1–S-40
drug resistance
mdr1 gene expression in primary vs. metastatic tumors 267-274
X-ray vs. drug induced resistance patterns in MCF-7 cells 23-39

EGF receptor
downregulation by ER in hormone dependent tumors 289-295
inverse correlation with EGF-like activity in tumor specimens 41-47
endocrine therapy
controlled release MPA, inhibition of DMBA rat mammary tumors 253-265
regression of rat DMBA tumors by a new aromatase inhibitor 15-21
resistance and molecular variants of ER and PR 119-130
tamoxifen resistance vs. true ER status 237-246
endometrium
proliferative changes with long-term tamoxifen 101-105
epidermal growth factor
see EGF
estrogen receptor
abnormalities in breast cancer (special issue) 117-202
and EGF receptor in hormone dependent vs. independent tumors 289-295
and immunohistochemical localization of cathepsin D 7-13
estrogen receptor (cont.)
association with hsp90 levels 95-100
by both ligand binding and immunohistochemistry, in tamoxifen resistance 237-246
dimerization, half-life, and pure antiestrogens 131-137
exon-skipping variants 163-174
genetic polymorphism associated with spontaneous abortion 175-180
loss in drug but not X-ray induced drug resistance 23-39
non-DNA-binding but immunoreactive variants in breast tumors 181-189
point mutation changes antiestrogen structure-function relationship 139-147
possible variants in ER+/PgR– breast tumors 191-202
truncated variants and alternative splicing 149-161
variants in ER-positive and nominally ER-negative cell lines 163-174
estrogen response element
non-binding ER variants in breast tumors 181-189
tumor protease activity mimicking non-DNA-binding ER 191-202
etoposide
in tandem non-cross resistant chemotherapy combinations S-3–S-9

fat intake
and mammographic parenchymal pattern 207-215

G-CSF
accelerated engraftment of hematopoietic progenitor cells S-19–S-23
in mobilizing peripheral blood progenitor cells S-25–S-29
graft-versus-host disease (GVHD)
induction and antitumor activity S-31–S-40
growth factors
paracrine interactions between hormone dependent and independent cell lines 275-281

heat shock proteins
hsp27 loss in drug but not X-ray induced drug resistance 23-39
hsp90 associated with estrogen receptor 95-100
Helix pomatia lectin (HPA)
binding as a prognostic factor 67-75
hematopoietic cell support
see bone marrow, peripheral blood stem cells
high-dose chemotherapy
in breast cancer (minisymposium) S-1–S-40
hormone dependence
and EGF receptor levels 289-295
paracrine interactions of dependent and independent cell lines 275-281
hormone resistance
and molecular variants of ER and PR 119-130
ER point mutation changes antiestrogen structure-function relationship 139-147
vs. ER status by both ligand binding and immunohistochemistry 237-246
HPA
see Helix pomatia lectin binding
4-hydroperoxycyclophosphamide
in marrow purging S-19–S-23

ICI 164384
pure antiestrogens and ER dimerization and half-life 131-137
ICI 182780
pure antiestrogens and ER dimerization and half-life 131-137
IGF-I (insulin-like growth factor I)
and paracrine interactions between hormone dependent and independent cell lines 275-281
immuno-chemotherapy
for liver metastases — immunological parameters 55-65
immunohistochemistry
quantitative cathepsin D, vs. other prognostic factors 7-13
immunological parameters
in patients with primary breast cancer vs. liver metastases 55-65
lymphocyte responses in breast cancer patients 77-88
interferon gamma
augmentation of GVHD induction and antitumor activity S-31–S-40
interleukin-2
in immuno-chemotherapy for liver metastases 55-65

keoxifene (antiestrogen)
ER point mutation changes structure-function relationship 139-147

LINE-1 sequences
in alternatively spliced ER variants 149-161
lymphocyte responses
to tumor antigens and general stimulators in breast cancer patients 77-88

mammographic parenchymal pattern
and dietary fat intake 207-215
marrow purging
4-hydroperoxycyclophosphamide/amifostine treatment S-19–S-23
MCF-7 cells
drug vs. X-ray induced drug resistance patterns 23-39
mdr1 gene
expression in primary vs. metastatic tumors 267-274
medroxyprogesterone acetate (MPA)
controlled release MPA, inhibition of DMBA rat mammary tumors 253-265
microspheres, poly[DL-lactide-co-glycolide]
controlled release MPA, inhibition of DMBA rat mammary tumors 253-265
mitomycin C
and navelbine in second line treatment 49-53
mitoxantrone
in tandem non-cross resistant chemotherapy combinations S-3–S-9
mixed lymphocyte tumor reaction
in immuno-chemotherapy for liver metastases 55-65
molecular variants
estrogen receptor (special issue) 117-202

multidrug resistance (MDR)
mdr1 gene expression in primary vs. metastatic tumors 267-274
see also drug resistance

natural killer cell activity
in immuno-chemotherapy for liver metastases 55-65
navelbine
and mitomycin C in second line treatment 49-53
nodal status
and *Helix pomatia* lectin binding 67-75

OK-432 (streptococcal immune stimulant)
in immuno-chemotherapy for liver metastases 55-65

P-glycoprotein
see drug resistance
p53
gene alterations and prognosis 225-235
paracrine interactions
co-culture of hormone dependent and independent cell lines 275-281
peripheral blood lymphocytes
in immuno-chemotherapy for liver metastases 55-65
peripheral blood progenitor cells
in reconstitution after high-dose chemotherapy S-25–S-29
pharmacokinetics
high-dose interactions of cisplatin and BCNU S-11–S-17
phosphotyrosine
elevation in breast cancer, by immunohistochemistry 217-224
platelet derived growth factor (PDGF)
in tumor tissue, vs. prognosis 247-252
ploidy
and *Helix pomatia* lectin binding, nodal status 67-75
progesterone receptor
and hsp90 levels 95-100
isoforms, antagonists, and function 127-128
status in hormone resistant tumors 237-246
progestin resistance
and molecular variants of ER and PR 119-130
progestin therapy
controlled release MPA, inhibition of DMBA rat mammary tumors 253-265
prognostic factors
cathepsin D, by immunohistochemistry 7-13
cathepsin D (discussion) 107-111
cyclic AMP binding proteins 89-94
EGF receptor vs. EGF-like activity in tumor specimens 41-47
Helix pomatia lectin binding 67-75
p53 gene alterations 225-235
phosphotyrosine and tyrosine kinase 217-224
platelet derived growth factor in tumor 247-252
tyrosine kinase activity 283-287
urinary testosterone 1-6
proliferative rate
by thymidine labelling, and cathepsin D 7-13
protein tyrosine kinase
see tyrosine kinase
pS2
loss in drug-induced but not X-ray-induced drug resistance 23-39
pulmonary toxicity
and high-dose drug interactions S-11–S-17
purging
4-hydroperoxycyclophosphamide/amifostine treatment of marrow S-19–S-23

recurrence
urinary testosterone as a marker 1-6
recurrence risk
see prognostic factors
RNA splicing
and estrogen receptor variants 117-118
RU 39,411 (antiestrogen)
ER point mutation changes structure-function relationship 139-147

single-stranded conformation polymorphism analysis
p53 gene alterations and prognosis 225-235
splicing variants
estrogen receptor and LINE-1 sequences 149-161

spontaneous abortion
association with estrogen receptor genetic polymorphism 175-180
stem cell transplantation
preparative drug regimens S-3–S-9
stem cells
accelerated engraftment by CD34+ selection S-19–S-23

T-cell growth factor
in immuno-chemotherapy for liver metastases 55-65
T-lymphocyte responses
to phytohemagglutinin and tumor antigens in breast cancer patients 77-88
tamoxifen
and endometrial proliferative changes 101-105
ER point mutation changes structure-function relationship 139-147
resistance and molecular variants of ER and PR 119-130
resistance and true ER status 237-246
testosterone
prognostic factor in urine 1-6
TGFα (transforming growth factor alpha)
and paracrine interactions between hormone dependent and independent cell lines 275-281
thiotepa
in tandem non-cross resistant chemotherapy combinations S-3–S-9
toxicity
and pharmacokinetics at high doses S-11–S-17
tumor antigens
T- and B-lymphocyte responses in breast cancer patients 77-88
tyrosine kinase
activity and prognosis 283-287
elevation in breast cancer 217-224

ultrasound
in evaluation of endometrial changes with long-term tamoxifen 101-105
urinary markers
testosterone and recurrence risk 1-6

VP-16
see etoposide

WR-2721
see amifostine

ZR-75-1 cells
drug vs. X-ray induced drug resistance patterns 23-39